Search the Newsreel

CRNX|Crinetics Pharmaceuticals Inc|Price:83.989|Chg%:+0.339

Crinetics Pharmaceuticals Inc. (CRNX) has a current stock price of $83.73, with a market capitalization of $8.86 billion. The company, which specializes in therapeutics for rare endocrine diseases, exhibits strong fundamentals and high growth potential, despite being considered fairly valued by analysts. Institutional ownership …

Neurocrine Biosciences (NBIX) Stock Trades Fair On Earnings But Mixed On Value

Neurocrine Biosciences (NBIX) stock has seen significant returns over the past five years, suggesting that current valuations might make it a hold rather than a clear bargain. The company's P/E ratio is fair compared to the biotech industry, and narratives vary from an underappreciated …

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

NBIX: Neurocrine Biosciences, Inc. Latest Stock Price, Analysis, News and Trading Ideas

This article provides details on Neurocrine Biosciences, Inc. (NBIX), including its latest stock price, key financial metrics like market cap and P/E ratio, and upcoming earnings date. It also links to recent news releases concerning the company's leadership changes and displays trending stock discussions.

Neurocrine Biosciences (NBIX) Appoints Samir Siddhanti To Lead Growth After $2.9 Billion Deal

Neurocrine Biosciences (NBIX) has appointed Samir Siddhanti as Chief Business Officer to lead business development, corporate strategy, and alliance management. This appointment follows the company's recent US$2.9 billion acquisition of Soleno Therapeutics and aims to formalize leadership for deal-making, pipeline shaping, and long-term growth. …

Neurocrine Biosciences (NBIX) Appoints Samir Siddhanti As Chief Business Officer

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Neurocrine Biosciences (NasdaqGS:NBIX) has appointed Samir Siddhanti as Chief Business Officer. Siddhanti will also join the company's executive Management Committee. The new role is focused …

Vertex was sole bidder in high-premium Crinetics acquisition

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Vertex Pharmaceuticals was the lone bidder in a planned, $10 billion acquisition that has some investors questioning whether the biotechnology giant overpaid …

How Crinetics Pharmaceuticals Inc. (CRNX) Affects Rotational Strategy Timing

The article analyzes Crinetics Pharmaceuticals Inc. (CRNX) using AI models to provide insights for rotational strategy timing. It suggests a near-term neutral sentiment but mid and long-term strength for CRNX, with no clear price positioning signal and compelling upside potential due to a lack …

Crinetics Pharmaceuticals (NASDAQ: CRNX) backs $85-per-share cash sale to Vertex

Crinetics Pharmaceuticals' Board of Directors has unanimously approved an $85-per-share all-cash acquisition by Vertex Pharmaceuticals. The deal, which values Crinetics at an attractive premium, follows extensive negotiations and a review of strategic alternatives. Shareholders will vote on the merger, which is expected to close …

Vertex-Crinetics Pharmaceuticals deal faces Australian review

Australia's antitrust watchdog, the Australian Competition & Consumer Commission (ACCC), is reviewing Vertex Pharmaceuticals' proposed acquisition of Crinetics Pharmaceuticals. The ACCC is concerned about the deal's potential impact on competition, given Vertex's existing product offerings in Australia and Crinetics' single product, Palsonify, which is …

Crinetics Pharmaceuticals (CRNX) Piper Sandler 36th Annual Healthcare Conference summary

Crinetics Pharmaceuticals presented at the Piper Sandler 36th Annual Healthcare Conference, highlighting advancements in their drug pipeline. Key updates include plans for an IND submission in 2025 for a Graves' disease and thyroid eye disease program, and an IND expected in early 2025 for …

CRNX: Pipeline advances in acromegaly, CAH, and NETs, with strong financial runway into 2030

Crinetics Pharmaceuticals (CRNX) is making significant progress with its pipeline targeting major endocrine diseases, including strong launch metrics for PALSONIFY in acromegaly. The company's drugs Atumelnant and CRN09682 are moving forward in late-stage trials for CAH, Cushing's, and neuroendocrine tumors. With $1.3 billion in …

Neurocrine Biosciences names Siddhanti chief business officer

Neurocrine Biosciences has appointed Samir Siddhanti as its new Chief Business Officer, where he will oversee business development, corporate strategy, alliance management, and program management. Siddhanti, who joined the company in 2017 and previously served as Vice President of Business Development, was instrumental in …

Crinetics Pharmaceuticals (CRNX) R&D Day 2025 Summary

Crinetics Pharmaceuticals (CRNX) presented a summary of its R&D Day 2025, highlighting its strategic focus on endocrine and endocrine-adjacent diseases with a patient-centric approach. The company detailed its expanding pipeline, including paltusotine, atumelnant, CRN09682, a TSH antagonist (CRN12755) for Graves’ Disease, and an SST3 …

Crinetics Pharmaceuticals (CRNX) Proxy filing Summary

Vertex Pharmaceuticals is set to acquire Crinetics Pharmaceuticals for approximately $10 billion ($8.8 billion net of cash), paying $85 per share in cash. This acquisition will bring PALSONIFY and atumelnant into Vertex's portfolio, with an expected combined peak annual revenue potential of over $5 …

Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching

Key Points Vertex Pharmaceuticals' latest acquisition grants it access to products with $5 billion peak annual sales potential. The company's business is strong thanks to its dominance in its core market and new launches in other areas. 10 stocks we like better than Vertex …

Neurocrine Biosciences (NBIX) Stock Looks Reasonable At Today’s Price

Neurocrine Biosciences (NBIX) stock is currently considered roughly fairly valued based on market multiples and a tailored P/E benchmark. While the company has shown strong returns over five years, its P/E ratio is above the biotech industry average. The article presents both bull and …

Is Neurocrine Biosciences (NBIX) Still Undervalued Or Does Its P E Leave Little Upside?

Neurocrine Biosciences (NBIX) stock has seen mixed short-term moves but strong long-term returns. Despite a narrative suggesting it's 11.4% undervalued with a fair value of $192.88 based on future growth and an extensive pipeline, its P/E ratio of 25.7x is higher than industry averages, …

Price to sales forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX

The article focuses on the "Price to sales forward" metric for Neurocrine Biosciences, Inc. (NASDAQ: NBIX) as displayed on TradingView. It provides financial data and an overview of the company's market performance. The content appears to be a stub or a section from a …

Crinetics Pharmaceuticals (CRNX) Stock Looks Fully Valued While Returns Stay Very Strong

Crinetics Pharmaceuticals (CRNX) has shown strong 5-year returns but its stock now appears fully valued, trading at a premium on traditional metrics, particularly its price-to-book ratio. Despite a proposed acquisition price of $85 per share and potential from its PALSONIFY and atumelnant programs, valuation …

NEUROCRINE BIOSCIENCES, INC. : WELLS FARGO RAISES TARGET PRICE TO $200 FROM $175

Wells Fargo has increased its target price for Neurocrine Biosciences, Inc. (NBIX.O) from $175 to $200. This update from Reuters indicates a positive outlook from the financial institution regarding the pharmaceutical company's valuation. The article briefly notes the published time from Reuters as 2026/07/17 …

Should Strong Earnings Projections and Zacks Rank #1 Status Require Action From Neurocrine Biosciences (NBIX) Investors?

Neurocrine Biosciences (NBIX) is projected to achieve 48.4% earnings growth this year and holds a Zacks Rank #1 (Strong Buy), indicating positive analyst sentiment. The article discusses how this strong outlook reinforces confidence in the company's focus on neurological and psychiatric disorders, specifically the …

Crinetics Pharmaceuticals (CRNX) Looks Fully Valued As Vertex Agrees $85 Per Share Deal

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals (CRNX) for $85 per share, totaling approximately $10 billion. Despite the offer being slightly above the average analyst target, some investors believe there's still residual value, with a "most popular narrative" valuing the company at $90 …

BofA Securities Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $199

BofA Securities has reiterated its Buy rating on Neurocrine Biosciences (NBIX.US) and set a price target of $199. This indicates a positive outlook from the analyst firm regarding the company's future stock performance.

Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals (CRNX) for $85 per share in an all-cash deal, valuing the acquisition at approximately $10 billion. The boards of both companies have unanimously approved the transaction, which is expected to close in Q3 of this year. …

Crinetics Pharmaceuticals Acquired by Fortress Biotech for $10 Billion

Fortress Biotech has acquired Crinetics Pharmaceuticals for approximately $10 billion, significantly enhancing its presence in the rare endocrine disease market. Crinetics' stock surged 99% on the news, despite facing profitability challenges and insider selling activity. The acquisition, expected to close in Q3 2026, aims …

Neurocrine’s 28% quarter reaches the range top with only 1.1x volume

NBIX closed within 0.6% of its 52-week high after a 6.5% week, but participation was only modest and the Sharemaestro read remains balanced rather than decisive.

UniCredit S.p.A.: Dividendenhistorie und Prognosen

UniCredit S.p.A.: Konsensus der Analysten und Kursziel | A2DJV6 | IT0005239360

UNICREDIT AKTIE Dividende | Hauptversammlung | Dividendenrendite | A2DJV6